Evgen Pharma PLC - clinical stage drug development company based in Liverpool - First patient enrolled in dosed in phase 2/3 Star trial of lead asset SFX-01 in acute respiratory distress syndrome. ARDS is caused by a build up of fluid in the lungs, which prevents the lungs from providing enough oxygen to vital organs. Evegen's study will investigate whether SFX-01: "Can reduce the severity, or prevent the onset of, acute respiratory distress syndrome in patients with community-acquired pneumonia who have been or are being tested for suspected Covid-19."
CEO Huw Jones: "The initiation of enrolment is an important milestone for us and marks the first use of SFX-01 in respiratory disease, targeting the Nrf2 pathway. We remain hopeful that the outcome of this trial will reduce both the severity and duration of the disease for Covid-19 patients and those with pneumonia from other infective agents."
Current stock price: 7.90 pence
Year-to-date change: up 11%
By Anna Farley; annafarley@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
